130 related articles for article (PubMed ID: 18158909)
41. Cysteine-specific PEGylation of rhG-CSF via selenylsulfide bond.
Kunstelj M; Fidler K; Skrajnar S; Kenig M; Smilović V; Kusterle M; Caserman S; Zore I; Porekar VG; Jevševar S
Bioconjug Chem; 2013 Jun; 24(6):889-96. PubMed ID: 23600957
[TBL] [Abstract][Full Text] [Related]
42. Solid phase pegylation of hemoglobin.
Suo X; Zheng C; Yu P; Lu X; Ma G; Su Z
Artif Cells Blood Substit Immobil Biotechnol; 2009; 37(4):147-55. PubMed ID: 19526439
[TBL] [Abstract][Full Text] [Related]
43. Erythrocytes as carriers of immunoglobulin-based therapeutics.
Ji W; Smith PN; Koepsel RR; Andersen JD; Baker SL; Zhang L; Carmali S; Myerson JW; Muzykantov V; Russell AJ
Acta Biomater; 2020 Jan; 101():422-435. PubMed ID: 31669698
[TBL] [Abstract][Full Text] [Related]
44. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
[TBL] [Abstract][Full Text] [Related]
45. Decreased immunorejection in unmatched blood transfusions by attachment of methoxypolyethylene glycol on human red blood cells and the effect on D antigen.
Tan Y; Qiu Y; Xu H; Ji S; Li S; Gong F; Zhang Y
Transfusion; 2006 Dec; 46(12):2122-7. PubMed ID: 17176324
[TBL] [Abstract][Full Text] [Related]
46. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
[TBL] [Abstract][Full Text] [Related]
47. Quantitative display of the redox status of proteins with maleimide-polyethylene glycol tagging.
Lee YJ; Chang GD
Electrophoresis; 2019 Feb; 40(4):491-498. PubMed ID: 30511403
[TBL] [Abstract][Full Text] [Related]
48. Influence of intramolecular cross-links on the molecular, structural and functional properties of PEGylated haemoglobin.
Hu T; Manjula BN; Li D; Brenowitz M; Acharya SA
Biochem J; 2007 Feb; 402(1):143-51. PubMed ID: 17049048
[TBL] [Abstract][Full Text] [Related]
49. Characterization of potential degradation products in a PEGylating reagent 20 kDa monomethoxy polyethylene glycol propionaldehyde by RP-HPLC, APCI-MS and NMR.
Zhang H; Wilson J; Zhang J; Luo Y
J Pharm Biomed Anal; 2014 Feb; 89():221-6. PubMed ID: 24316423
[TBL] [Abstract][Full Text] [Related]
50. Design and Synthesis of an Easily Obtainable Maleimide Reagent N-[2-(4-[
Fujita Y; Murakami Y; Noda A; Miyoshi S
Bioconjug Chem; 2017 Feb; 28(2):642-648. PubMed ID: 27936600
[TBL] [Abstract][Full Text] [Related]
51. A method to optimize PEG-coating of red blood cells.
Hashemi-Najafabadi S; Vasheghani-Farahani E; Shojaosadati SA; Rasaee MJ; Armstrong JK; Moin M; Pourpak Z
Bioconjug Chem; 2006; 17(5):1288-93. PubMed ID: 16984140
[TBL] [Abstract][Full Text] [Related]
52. Stability of Maleimide-PEG and Mono-Sulfone-PEG Conjugation to a Novel Engineered Cysteine in the Human Hemoglobin Alpha Subunit.
Cooper CE; Bird M; Sheng X; Choi JW; Silkstone GGA; Simons M; Syrett N; Piano R; Ronda L; Bettati S; Paredi G; Mozzarelli A; Reeder BJ
Front Chem; 2021; 9():707797. PubMed ID: 34381760
[TBL] [Abstract][Full Text] [Related]
53. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors.
Luo G; Yu X; Jin C; Yang F; Fu D; Long J; Xu J; Zhan C; Lu W
Int J Pharm; 2010 Jan; 385(1-2):150-6. PubMed ID: 19825404
[TBL] [Abstract][Full Text] [Related]
54. Comparative binding of disulfide-bridged PEG-Fabs.
Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
[TBL] [Abstract][Full Text] [Related]
55. Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase.
Colonna C; Conti B; Perugini P; Pavanetto F; Modena T; Dorati R; Iadarola P; Genta I
Int J Pharm; 2008 Jun; 358(1-2):230-7. PubMed ID: 18455892
[TBL] [Abstract][Full Text] [Related]
56. The synthesis of a carbon-14 labeled pegylated Adnectin™ for placental transfer studies in guinea pigs.
Maxwell BD; Cao K; Bonacorsi S; Sivaraman L; Wang B; McNerney M; Wang L; Christopher LJ; Fung NK; Wang J; Arnold ME
J Labelled Comp Radiopharm; 2013; 56(9-10):492-4. PubMed ID: 24285527
[TBL] [Abstract][Full Text] [Related]
57. Hexa-thiocarbamoyl phenyl PEG5K Hb: vasoactivity and structure: influence of rigidity of the conjugation linkage on the PEGylation induced plasma expander-like solution properties of PEG-Hb adducts.
Meng F; Manjula BN; Tsai AG; Cabrales P; Intaglietta M; Smith PK; Prabhakaran M; Acharya SA
Protein J; 2009 Jun; 28(5):199-212. PubMed ID: 19653083
[TBL] [Abstract][Full Text] [Related]
58. The disulfide linkage and the free sulfhydryl accessibility of acyl-coenzyme A:cholesterol acyltransferase 1 as studied by using mPEG5000-maleimide.
Guo ZY; Chang CC; Lu X; Chen J; Li BL; Chang TY
Biochemistry; 2005 May; 44(17):6537-46. PubMed ID: 15850387
[TBL] [Abstract][Full Text] [Related]
59. PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery.
Qian Y; Zha Y; Feng B; Pang Z; Zhang B; Sun X; Ren J; Zhang C; Shao X; Zhang Q; Jiang X
Biomaterials; 2013 Mar; 34(8):2117-29. PubMed ID: 23245924
[TBL] [Abstract][Full Text] [Related]
60. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
